Metacrine Receivables

Metacrine (MTCR) currently reports a receivables of $55K as of September 2022. That compares with $67K in the prior-year period — down 17.9% year over year. Use the charts on this page to explore Metacrine's receivables history and peer comparisons.

Metacrine's receivables decreased from $67K to $55K — a 17.9% year-over-year decrease (period ending September 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Metacrine reported $55K in receivables as of September 2022. That compares with $67K in the prior-year period — down 17.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $55K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Metacrine, and consider following MTCR for alerts when major investors trade the stock.

Metacrine is classified in the Healthcare sector. On receivables, it currently shows $55K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing MTCR with unrelated industries.